Smart MR Imaging Agents Relevant to Potential Neurologic Applications

References

1. 1.↵
   1. Merbach AE,
   2. Toth E

   . The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chichester, UK: John Wiley & Sons; 2001
2. 2.↵
   1. Caravan P,
   2. Ellison JJ,
   3. McMurry TJ,
   4. et al

   . Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999;99:2293–352

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Allen MJ,
   2. Meade TJ

   . Magnetic resonance contrast agents for medical and molecular imaging. Met Ions Biol Syst 2004;42:1–38

   PubMedWeb of Science
4. 4.↵
   1. Aime S,
   2. Delli Castelli D,
   3. Terreno E

   . Novel pH-reporter MRI contrast agents. Angew Chem Int Ed Engl 2002;41:4334–36

   CrossRefPubMed
5. 5.↵
   1. Zhang S,
   2. Winter P,
   3. Wu K,
   4. et al

   . A novel europium(III)-based MRI contrast agent. J Am Chem Soc 2001;123:1517–18

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Woods M,
   2. Woessner DE,
   3. Sherry AD

   . Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem Soc Rev 2006;35:500–11

   CrossRefPubMed
7. 7.↵
   1. Woessner DE,
   2. Zhang S,
   3. Merritt ME,
   4. et al

   . Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI. Magn Reson Med 2005;53:790–99

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Sherry AD,
   2. Woods M

   . Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng 2008;10:391–411

   CrossRefPubMed
9. 9.↵
   1. Hammoud DA,
   2. Hoffman JM,
   3. Pomer MG

   . Molecular neuroimaging: from conventional to emerging techniques. Radiology 2007;245:21–42

   CrossRefPubMed
10. 10.↵
    1. Jasanoff A

    . MRI contrast agents for functional molecular imaging of brain activity. Curr Op Neurobiol 2007;17:593–600

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Que LE,
    2. Domaille DW,
    3. Chang CJ

    Metals in neurobiology: probing their chemistry and biology with molecular imaging. Chem Rev 2008;108:1517–49

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Logothetis NK

    . What we can do and what we cannot do with fMRI. Nature 2008;453:869–78

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Waters J,
    2. Larkum M,
    3. Sakmann B,
    4. et al

    . Supralinear Ca²⁺ influx into dendritic tufts of layer 2/3 neocortical pyramidal neurons in vitro and in vivo. J Neurosci 2003;23:8558–67

    Abstract/FREE Full Text
14. 14.↵
    1. Kerr JND,
    2. Greenberg D,
    3. Helmchen F

    . From the cover: imaging input and output of neocortical networks in vivo. Proc Natl Acad Sci U S A 2005;102:14063–68

    Abstract/FREE Full Text
15. 15.↵
    1. Ohki K,
    2. Chung S,
    3. Ch'ng YH,
    4. et al

    . Functional imaging with cellular resolution reveals precise micro-architecture in visual cortex. Nature 2005;433:597–603. Epub 2005 Jan 19

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Somjen GG

    . Ions in the Brain: Normal Function, Seizures, and Stroke. Oxford, UK: Oxford University Press; 2004
17. 17.↵
    1. Koller CW

    . Neuroprotective therapy for Parkinson's disease. Exp Neurol 1997;144:24–28

    CrossRefPubMed
18. 18.↵
    1. Panov AV,
    2. Burke JR,
    3. Strittmatter WJ,
    4. et al

    . In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch Biochem Biophys 2003;410:1–6

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Yan HD,
    2. Lim W,
    3. Lee KW,
    4. et al

    . Sera from amyotrophic lateral sclerosis patients reduce high-voltage activated Ca²⁺ currents in mice dorsal root ganglion neurons. Neurosci Lett 1997;235:69–72

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Jimerson DC,
    2. Post RM,
    3. Carman JS,
    4. et al

    . CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry 1979;14:37–51

    PubMedWeb of Science
21. 21.↵
    1. Yarlagadda A

    . Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions. Med Hypotheses 2002;58:182–86

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Gailly P

    . New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim Biophys Acta 2002;1600:38–44

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Lin YJ,
    2. Koretsky AP

    . Manganese ion enhances T1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med 1997;38:378–88

    PubMedWeb of Science
24. 24.↵
    1. Koretsky AP,
    2. Silva AC

    . Manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed 2004;17:527–31

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Atanasijevic T,
    2. Shusteff M,
    3. Fam P,
    4. et al

    . Calcium-sensitive MRI contrast agents based on superparamagnetic iron oxide nanoparticles and calmodulin. Proc Natl Acad Sci U S A 2006;103:14707–712

    Abstract/FREE Full Text
26. 26.↵
    1. Shapiro MG,
    2. Atanasijevic T,
    3. Faas H,
    4. et al

    . Dynamic imaging with MRI contrast agents: quantitative considerations. Magn Res Imaging 2006;24:449–62

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Li W,
    2. Fraser SE,
    3. Meade TJ

    . A calcium-sensitive magnetic resonance imaging contrast agent. J Am Chem Soc 1999;12:1413–14
28. 28.↵
    1. Dhingra K,
    2. Fousková P,
    3. Angelovski G,
    4. et al

    . Towards extracellular Ca2+ sensing by MRI: synthesis and calcium-dependent 1H and 17O relaxation studies of two novel bismacrocyclic Gd³⁺ complexes. J Biol Inorg Chem 2008;13:35–46. Epub 2007 Sep 15

    CrossRefPubMed
29. 29.↵
    1. Mishra A,
    2. Fousková P,
    3. Angelovski G,
    4. et al

    . Facile synthesis and relaxation properties of novel bispolyazamacrocyclic Gd(3+) complexes: an attempt towards calcium-sensitive MRI contrast agents. Inorg Chem 2008;47:1370–81. Epub 2008 Mar 28

    CrossRefPubMed
30. 30.↵
    1. Angelovski G,
    2. Fousková P,
    3. Mamedov I,
    4. et al

    . Smart MRI agents sensing extracellular calcium fluctuations. Chembiochem 2008;9:1729–34

    CrossRefPubMed
31. 31.↵
    1. Dhingra K,
    2. Maier ME,
    3. Beyerlein M,
    4. et al

    . Synthesis and characterization of a smart contrast agent sensitive to calcium. Chem Commun (Camb) 2008;3444–46. Epub 2008 Jun 4
32. 32.↵
    1. Faller P,
    2. Hureau C

    . Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans 2009:1080–94. Epub 2008 Nov 26
33. 33.↵
    1. Hanaoka K,
    2. Kikuchi K,
    3. Urano Y,
    4. et al

    . Selective sensing of zinc ions with a novel magnetic resonance imaging contrast agent. J Chem Soc Perkin Trans 2 2001:1840
34. 34.↵
    1. Hanaoka K,
    2. Kikuchi K,
    3. Urano Y,
    4. et al

    . Design and synthesis of a novel magnetic resonance imaging contrast agent for selective sensing of zinc ion. Chem Biol 2002;9:1027–32

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Major JL,
    2. Boiteau RM,
    3. Meade TJ

    . Mechanisms of ZnII-activated resonance imaging agents. Inorg Chem 2008;47:10788–95. Epub 2008 Oct 18

    CrossRefPubMed
36. 36.↵
    1. Major JL,
    2. Parigi G,
    3. Luchinat C,
    4. et al

    . The synthesis and in vitro testing of a zinc-activated MRI contrast agent. Proc Natl Acad Sci U S A 2007;104:13881–86

    Abstract/FREE Full Text
37. 37.↵
    1. Trokowski R,
    2. Ren J,
    3. Kalman FK,
    4. et al

    . Selective sensing of zinc ions with a PARACEST contrast agent. Angew Chem Int Ed Engl 2005;44:6920–23

    CrossRefPubMed
38. 38.↵
    1. Paris J,
    2. Gameiro C,
    3. Humblet V,
    4. et al

    . Auto-assembling of ditopic macrocyclic lanthanide chelates with transition-metal ions: rigid multimetallic high relaxivity contrast agents for magnetic resonance imaging. Inorg Chem 2006;45:5092–102

    CrossRefPubMed
39. 39.↵
    1. Livramento JB,
    2. Toth E,
    3. Sour A,
    4. et al

    . High relaxivity confined to a small molecular space: a metallostar-based, potential MRI contrast agent. Angew Chem Int Ed Engl 2005;44:1480–84

    CrossRefPubMed
40. 40.↵
    1. Livramento JB,
    2. Sour A,
    3. Borel A,
    4. et al

    . A starburst-shaped heterometallic compound incorporating six densely packed Gd(3+) ions. Chemistry 2006;12:989–1003

    CrossRefPubMed
41. 41.↵
    1. Livramento JB,
    2. Weidensteiner C,
    3. Prata MI,
    4. et al

    . First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity. Contrast Media Mol Imaging 2006;1:30–39

    CrossRefPubMed
42. 42.↵
    1. Parac-Vogt TN,
    2. Vander Elst L,
    3. Kimpe K,
    4. et al

    . Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity. Contrast Med Mol Imaging 2006;1:267–78

    CrossRef
43. 43.↵
    1. Jacques V,
    2. Desreux JF

    . New classes of MRI contrast agents. Top Curr Chem 2002;221:125–64
44. 44.↵
    1. Aime S,
    2. Botta M,
    3. Fasano M,
    4. et al

    . Paramagnetic GdIII-FeIII heterobimetallic complexes of DTPA-bis-salicylamide. Spectrochimica Acta 1993;9:1315–22
45. 45.↵
    1. Gaggelli E,
    2. Kozlowsky H,
    3. Valensin D,
    4. et al

    . Copper homeostasis and neurodegenerative disorders (Alzheimer's prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev 2006;106:1995–2044

    CrossRefPubMedWeb of Science
46. 46.↵
    1. Que EL,
    2. Chang CJ

    . A smart magnetic resonance contrast agent for selective copper sensing. J Am Chem Soc 2006;128:15942–43

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Gillies RJ,
    2. Raghunand N,
    3. Karczmar GS,
    4. et al

    . MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430–50

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Chesler M

    . Regulation and modulation of pH in the brain. Physiol Rev 2003;83:1183–221

    Abstract/FREE Full Text
49. 49.↵
    1. Kalman FK,
    2. Woods M,
    3. Caravan P,
    4. et al

    . Potentiometric and relaxometric properties of a gadolinium-based MRI contrast agent for sensing tissue pH. Inorg Chem 2007;46:5260–70

    CrossRefPubMed
50. 50.↵
    1. Aime S,
    2. Crich SG,
    3. Gianolio E,
    4. et al

    . High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev 2006;250:1562–79

    CrossRef
51. 51.↵
    1. Mikawa M,
    2. Miwa N,
    3. Brautigam M,
    4. et al

    . A pH-sensitive contrast agent for functional magnetic resonance imaging (MRI). Chem Lett 1998;7:693–94
52. 52.↵
    1. Aime S,
    2. Crich SG,
    3. Botta M,
    4. et al

    . A macromolecular Gd(III) complex as pH-responsive relaxometric probe for MRI applications. Chem Commun 1999:1577–78
53. 53.↵
    1. Lowe MP,
    2. Parker D,
    3. Reany O,
    4. et al

    . pH-dependent modulation of relaxivity and luminescence in macrocyclic gadolinium and europium complexes based on reversible intramolecular sulfonamide ligation. J Am Chem Soc 2001;123:7601–09

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Hovland R,
    2. Glogard C,
    3. Aasen AJ,
    4. et al

    . Gadolinium DO3A derivatives mimicking phospholipids; preparation and in vitro evaluation as pH responsive MRI contrast agents. J Chem Soc Perkin Trans 2 2001;6:929–33
55. 55.↵
    1. Toth E,
    2. Bolskar RD,
    3. Borel A,
    4. et al

    . Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J Am Chem Soc 2005;127:799–805

    CrossRefPubMedWeb of Science
56. 56.↵
    1. Zhang S,
    2. Wu K,
    3. Sherry AD

    . A novel pH-sensitive MRI contrast agent. Angew Chem Int Ed Engl 1999;38:3192–94

    CrossRefPubMed
57. 57.↵
    1. Raghunand N,
    2. Howison C,
    3. Sherry AD,
    4. et al

    . Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med 2003;49:249–57

    CrossRefPubMedWeb of Science
58. 58.↵
    1. Garcia-Martin ML,
    2. Martinez GV,
    3. Raghunand N,
    4. et al

    . High-resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med 2006;55:309–15

    CrossRefPubMed
59. 59.↵
    1. Ali MM,
    2. Woods M,
    3. Caravan P,
    4. et al

    . Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent. Chemistry 2008;14:7250–58

    CrossRefPubMed
60. 60.↵
    1. Ward KM,
    2. Balaban RS

    . Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magn Reson Med 2000;44:799–802

    CrossRefPubMedWeb of Science
61. 61.↵
    1. Aime S,
    2. Barge A,
    3. Delli Castelli D,
    4. et al

    . Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications. Magn Reson Med 2002;47:639–48

    CrossRefPubMedWeb of Science
62. 62.↵
    1. Terreno E,
    2. Delli Castelli D,
    3. Cravotto G,
    4. et al

    . Ln(III)-DOTAMGly complexes: a versatile series to assess the determinants of the efficacy of paramagnetic chemical exchange saturation transfer agents for magnetic resonance imaging applications Invest Radiol 2004;39:235–43

    CrossRefPubMed
63. 63.↵
    1. Moats RA,
    2. Fraser SE,
    3. Meade TJ

    . A “smart” magnetic resonance imaging agent that reports on specific enzymatic activity. Angew Chem Int Ed Engl 1997;36:726–28

    CrossRefWeb of Science
64. 64.↵
    1. Louie AY,
    2. Hüber MM,
    3. Ahresn ET,
    4. et al

    . In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18:321–25

    CrossRefPubMedWeb of Science
65. 65.↵
    1. Anelli PL,
    2. Bertini I,
    3. Fragai M,
    4. et al

    . Sulfonamide-functionalized gadolinium DTPA complexes as possible contrast agents for MRI: a relaxometric investigation. Eur J Inorg Chem 2000:625–30
66. 66.↵
    1. Nivorozhkin AL,
    2. Kolodziej AF,
    3. Caravan P,
    4. et al

    . Enzyme-activated Gd(III) magnetic resonance imaging contrast agents with a prominent receptor-induced magnetization enhancement. Angew Chem Int Ed Engl 2001;40:2903–06

    CrossRefPubMed
67. 67.↵
    1. Lauffer RB,
    2. McMurry TJ,
    3. Dunham SO,
    4. et al

    . Epix Medical Inc. Bioactivated diagnostic imaging contrast agents. Patent publication number WO9736619. 10 9, 1997
68. 68.↵
    1. Mazooz G,
    2. Mehlman T,
    3. Lai TS,
    4. et al

    . Development of magnetic resonance imaging contrast material for in vivo mapping of tissue transglutaminase activity. Cancer Res 2005;65:1369–75

    Abstract/FREE Full Text
69. 69.↵
    1. Shiftan L,
    2. Israely T,
    3. Cohen M,
    4. et al

    . Magnetic resonance imaging visualization of hyaluronidase in ovarian carcinoma. Cancer Res 2005;65:10316–23

    Abstract/FREE Full Text
70. 70.↵
    1. Chen JW,
    2. Pham W,
    3. Weissleder R,
    4. et al

    . Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn. Reson Med 2004;52:1021–28

    CrossRefPubMedWeb of Science
71. 71.↵
    1. Querol M,
    2. Chen JW,
    3. Weissleder R,
    4. et al

    . DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org Lett 2005;7:1719–22

    CrossRefPubMedWeb of Science
72. 72.↵
    1. Duimstra JA,
    2. Femia FJ,
    3. Meade TJ

    . A gadolinium chelate for detection of beta-glucuronidase: a self-immolative approach. J Am Chem Soc 2005;127:12847–55

    CrossRefPubMed
73. 73.↵
    1. Yoo B,
    2. Pagel MD

    . A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc 2006;128:14032–33

    CrossRefPubMed
74. 74.↵
    1. Yoo B,
    2. Raam MS,
    3. Rosenblum RM,
    4. et al

    . Enzyme-responsive PARACEST MRI contrast agents: new biomedical imaging approach for studies of the proteasome. Contrast Media Mol Imaging 2007;2:189–98

    CrossRefPubMed
75. 75.↵
    1. Chauvin T,
    2. Durand P,
    3. Bernier M,
    4. et al

    . Detection of enzymatic activity by PARACEST MRI: a general approach to target a large variety of enzymes. Angew Chem Int Ed Engl 2008;47:4370–72

    CrossRefPubMed
76. 76.↵
    1. Raghunand N,
    2. Gatenby RA,
    3. Gillies RJ

    . Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003;76:S11–S22

    Abstract/FREE Full Text
77. 77.↵
    1. Rofstad EK

    . Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000;76:589–605

    CrossRefPubMedWeb of Science
78. 78.↵
    1. Raghunand N,
    2. Gillies RJ

    . pH and drug resistance in tumors. Drug Resist Updat 2000;3:39–47

    CrossRefPubMed
79. 79.↵
    1. Matsumoto H,
    2. Inoue N,
    3. Takaoka H,
    4. et al

    . Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction. Clin Cardiol 2004;27:466–70

    PubMedWeb of Science
80. 80.↵
    1. Aime S,
    2. Botta M,
    3. Gianolio E,
    4. et al

    . A pO2-responsive MRI contrast agent based on the redox switch of manganese (II/III)-porphyrin complexes. Angew Chem Int Ed 2000;39:747–50

    CrossRefPubMed
81. 81.↵
    1. Raghunand N,
    2. Jagadish B,
    3. Trouard TP,
    4. et al

    . Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 2006;55:1272–80

    CrossRefPubMed
82. 82.↵
    1. Ratnakar SJ,
    2. Woods M,
    3. Lubag AJ,
    4. et al

    . Modulation of water exchange in europium(III) DOTA-tetraamide complexes via electronic substituent effects. J Am Chem Soc 2008;130:6–7. Epub 2007 Dec 8

    CrossRefPubMed